The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Add another 20 million today
Looks great for a retake - 100 million isn’t enough for a company that has just been given 20 million with potential 1.8 billion on payments for full commercial sales on only one of there drugs
SLN in the last three years has seen its sp drop from £3 to around 60p. Today after what can only be described as a game changer sees the company in bed with a massive party. Truly massive and they clearly really like SLN. So much so they will have executive presence on the SLN board Will buy $5M of shares AND give SLN an u front payment of $20M. Thanks very much guys!!!
So whats next Well the FT has commented on the collaboration. Proactive released a summary pretty dam quick and last but not least could this lead to an IPO? Might our new business partner increase their stake. I would if I was them unless there is an exclusion clause in this deal?
The future of SLN is completely assured which can only mean an increase in the sp from here. The americans without doubt will be getting wind f this new collaboration and will be looking to buy shares. There is no way anyone should sell these shares. This share long term will give its shareholders a massive return. Be patient and wait for your capital to grow. I am!!!
By the way this deal is only for two of the company's assets TWO!!!!! and long term is worth over £1B plus royalties !!
I have not seen much comment on the following:
'Silence would also receive tiered, low double-digit to high-teen royalties on net sales for SLN500 and each optioned asset'
Has anyone seen any revenue projections regarding the above bandied about? The words 'also receive' caught my eye......
There is a lot of detail in the 2 x RNSs. Welldone to CEO for holding conference call so soon after RNS. Once news is properly digested, we should see a lot better SP. Interestingly alongside the $5m placing they also get initial US$20M upfront!
Manipulation on this SP has been staggering and unbelievable today. Every little rise followed by series of sells..and these were like 10-20 sells instantly. It’s exactly what’s wrong with the markets. If MMs going to allow it on such significant monumental news then it’s no longer investable news, you’d rather just trade it. MMs marked this 50% on just a few handful of trades, then at 1.3 SP they were asking £2/share!
Silence Therapeutics agrees major collaboration with US firm Mallinckrodt
Share
13:00 18 Jul 2019
Silence said the collaboration has the potential to bring in up to US$2bn in clinical, regulatory and commercial payments for its assets
https://www.proactiveinvestors.co.uk/companies/news/224143/silence-therapeutics-agrees-major-collaboration-with-us-firm-mallinckrodt-224143.html
That’s normal with any funding...they’re not going to hand you all the money upfront are they..lol. Important thing is they’ve secured hugh funding and a hugh partner!
I guess we also have to remember the numbers being quoted by some are at least two years away. They need to start human trials first which we have no date
Gonna be a long burner
https://www.google.com/search?fs&q=Silence+Therapeutics&ie=utf-8&oe=utf-8
Sorry didn't know you had to subscribe. If you click the link from google search of 'Silence Therapeutics' - the FT link appears in Top Stories and when clicked you are able to view articles without the requested subscription requirement.
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/d37a236e-a940-11e9-984c-fac8325aaa04
Silence Therapeutics nearly doubled after the gene science developer licensed its flagship technology to Mallinckrodt Pharmaceuticals.
The US-based, Ireland-domiciled drugmaker paid a $20m upfront payment as well as agreeing up to $666m in milestone payments and around $10m in research funding in exchange for exclusive rights to Silence’s SLN 500, an early-stage experimental drug that aims to regulate immune responses. Mallinckrodt also took options to sign similarly structured deals over two drugs in Silence development pipeline.
Copy and Paste - no subscription no read...
https://www.ft.com/content/d37a236e-a940-11e9-984c-fac8325aaa04
over a quarter of a Million GBP dealt in one single trade !...
ITs simply outrageous they allow it on absolutely company changing news..bets this would have 1-2 bagged on a Twitter rumour about this deal!
143.50
200,000
287.00k GBP
Stupid MM’s looking for a speeding ticket!
Bunch of ****s!
MMs inept can not regulate jack all, letting the manipulators control the SP..it’s all that is wrong with the markets...deeply frustrating for investors..
With the money that goes into R and D for drugs/science, to get to production, this deal/deals has all the hallmarks of a major rerate for SLN and will far exceed previous highs. AIMHO
Mind boggling collaboration tbh, It's true we're talking approx £2 Billion. Like I said earlier, a board seat for Mallinckrodt for £5mil worth of shares plants them with SLN as an assured investment, which to me means they can't sell unless they're giving up the board seat... and can't see that happening until milestones are achieved.... by which time they're shares of £5 mil will be worth a boggling amount!
It’s $703m per additional asset of which there are two so over $1.4 billion plus the $563 million for SLN500 so approx $2bn in total. This excludes their pipeline of other assets which fall outside the terms of this agreement.
So potentially billions not millions!
Get ready got the feeling this is now ready to get to the next level..
Mallinckrodt has agreed to provide Silence with an upfront payment of $20 million. Silence is also eligible to receive up to $10 million in research milestones for SLN500 and for each optioned asset, in addition to funding for Phase 1 clinical development including GMP[4] manufacturing. Silence will fund all other preclinical activities. The collaboration provides for potential added clinical and regulatory milestone payments of up to $100 million for SLN500, as well as commercial milestone payments of up to $563 million for SLN500. Should Mallinckrodt opt to license one or two additional assets, Silence could receive up to $703 million in similar clinical, regulatory, and commercial milestone payments per asset. Silence would also receive tiered, low double-digit to high-teen royalties on net sales for SLN500 and each optioned asset.
Yes why do they want to do that ? Unless they’re just waiting for the traders to get out..which now is there time to clear desk for the day..
Up and down. £1.47 then £1.35
Problem is it puts people off as it’s too risky if your trading it
Seriously MMs..let go! Most no brainer RNS and here we are playing around with pennies lol